Evidence map›Paper›PMID 32766851›Full record

ArticleJournal of the National Cancer Institute2021

Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies.

Alice W Lee, Stacey Rosenzweig, Ashley Wiensch, Australian Ovarian Cancer Study Group, Susan J Ramus, Usha Menon, Aleksandra Gentry-Maharaj, Argyrios Ziogas, Hoda Anton-Culver, Alice S Whittemore and 36 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Global epidemiology of epithelial ovarian cancer.Nature reviews. Clinical oncology · 2024
    Review
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.Diagnostics (Basel, Switzerland) · 2022
    Article
  11. The Features ofInternational journal of general medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors at 20 institutions in 5 countries.

Alice W LeeDepartment of Public Health, California State University, Fullerton, Fullerton, CA, USA.
Stacey RosenzweigDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Ashley WienschDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Australian Ovarian Cancer Study Group
Susan J RamusSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia.
Usha MenonAdult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
Aleksandra Gentry-MaharajAdult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
Argyrios ZiogasMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
Hoda Anton-CulverMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
Alice S WhittemoreDepartment of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
Weiva SiehDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Joseph H RothsteinDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Valerie McGuireDepartment of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Bo QinCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Kathryn L TerryDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Daniel W CramerDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Linda TitusDepartments of Epidemiology and of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Joellen M SchildkrautDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA.
Ellen L GoodeDivision of Epidemiology, Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.
Susanne K KjaerDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Allan JensenDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Susan J JordanPopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Roberta B NessSchool of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.
Francesmary ModugnoWomens Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA.
Kirsten MoysichDivision of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Pamela J ThompsonSamuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Marc T GoodmanSamuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael E CarneyDepartment of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Holly R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jennifer Anne DohertyDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Harvey A RischChronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Lilah KhojaDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Aliya AlimujiangDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Minh Tung PhungDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Katharine BriegerDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Bhramar MukherjeeDepartment of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Paul D P PharoahDepartment of Oncology, University of Cambridge, Cambridge, UK.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Penelope M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Celeste Leigh PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
University of Michigan · USRutgers, The State University of New Jersey · USUniversity of California, Irvine · USUniversity of Southern California · USBrigham and Women's Hospital · USCancer Institute of New South Wales · AUCedars-Sinai Medical Center · USEmory University · USStanford University · USThe University of Queensland · AUUniversity of Copenhagen · DKUniversity of Hawaiʻi at Mānoa · USUniversity of Washington · USCalifornia State University, Fullerton · USDuke Medical Center · USIcahn School of Medicine at Mount Sinai · USMRC Clinical Trials Unit at UCL · GBNational Cancer Institute · USQIMR Berghofer Medical Research Institute · AURoswell Park Comprehensive Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
Northern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1985 to 2009
$18.2M
University of Michigan Training Program in Genomic ScienceT32HG000040 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sebastian Zoellner · 1995 to 2026
$16.4M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISMR01CA054419 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 1992 to 2007
$5.9M
Cancer Research UK 16561Medical Research Council MC_UU_00004/01Medical Research Council MC_UU_12023/20NCI NIH HHS K07 CA080668NCI NIH HHS K07 CA095666NCI NIH HHS K22 CA138563NCI NIH HHS K22 CA193860NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA072720NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA080742NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA248288NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS U01 CA069417NCI NIH HHS U19 CA148112NHGRI NIH HHS T32 HG000040
6 · The paper itself

Abstract

backgroundParity is associated with decreased risk of invasive ovarian cancer; however, the relationship between incomplete pregnancies and invasive ovarian cancer risk is unclear. This relationship was examined using 15 case-control studies from the Ovarian Cancer Association Consortium (OCAC). Histotype-specific associations, which have not been examined previously with large sample sizes, were also evaluated.

methodsA pooled analysis of 10 470 invasive epithelial ovarian cancer cases and 16 942 controls was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between incomplete pregnancies and invasive epithelial ovarian cancer were estimated using logistic regression. All models were conditioned on OCAC study, race and ethnicity, age, and education level and adjusted for number of complete pregnancies, oral contraceptive use, and history of breastfeeding. The same approach was used for histotype-specific analyses.

resultsEver having an incomplete pregnancy was associated with a 16% reduction in ovarian cancer risk (OR = 0.84, 95% CI = 0.79 to 0.89). There was a trend of decreasing risk with increasing number of incomplete pregnancies (2-sided Ptrend < .001). An inverse association was observed for all major histotypes; it was strongest for clear cell ovarian cancer.

conclusionsIncomplete pregnancies are associated with a reduced risk of invasive epithelial ovarian cancer. Pregnancy, including incomplete pregnancy, was associated with a greater reduction in risk of clear cell ovarian cancer, but the result was broadly consistent across histotypes. Future work should focus on understanding the mechanisms underlying this reduced risk.

Indexed as

Abortion, InducedAbortion, SpontaneousCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleHumansOvarian NeoplasmsParityPregnancyRiskUnited KingdomUnited States

Identifiers

PMID32766851
PMCPMC7936053
OpenAlexW3048150977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.